Market overview
The global radiopharmaceuticals market is worth USD 12.1 bn in 2026 and is forecast to reach USD 39.3 bn by 2036, growing at a 12.5% CAGR. United States is the largest country market and Therapeutic is the largest by use segment.
| Scope | Radioactive drugs used for diagnostic imaging (PET and SPECT tracers) and targeted therapy, including technetium-99m, fluorine-18 agents, lutetium-177 and radium-223 products. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 10.8 bn |
| Value 2026 | USD 12.1 bn |
| Value 2036 | USD 39.3 bn |
| CAGR 2026-2036 | 12.5% |
| Volume 2026 | 51.3 million doses |
| Volume 2036 | 158 million doses |
| Average price 2026 | USD 236 per dose |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Radiopharmaceuticals market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 12.1 bn |
| 2027 | USD 13.6 bn |
| 2028 | USD 15.3 bn |
| 2029 | USD 17.2 bn |
| 2030 | USD 19.4 bn |
| 2031 | USD 21.8 bn |
| 2032 | USD 24.5 bn |
| 2033 | USD 27.6 bn |
| 2034 | USD 31.0 bn |
| 2035 | USD 34.9 bn |
| 2036 | USD 39.3 bn |
Radiopharmaceuticals market segmentation
By use
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Diagnostic SPECT | 30.0% | 13.9% | USD 3.6 bn | 4.2% |
| Diagnostic PET | 34.0% | 27.6% | USD 4.1 bn | 10.2% |
| Therapeutic | 36.0% | 58.5% | USD 4.4 bn | 18.1% |
By isotope
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Technetium-99m | 22.0% | 9.0% | USD 2.7 bn | 2.9% |
| Fluorine-18 | 26.0% | 18.6% | USD 3.1 bn | 8.8% |
| Gallium-68 and others PET | 10.0% | 8.6% | USD 1.2 bn | 10.8% |
| Lutetium-177 | 28.0% | 51.9% | USD 3.4 bn | 19.7% |
| Other therapeutic and diagnostic | 14.0% | 12.0% | USD 1.7 bn | 10.8% |
By application
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Oncology | 62.0% | 75.8% | USD 7.5 bn | 14.8% |
| Cardiology | 20.0% | 10.8% | USD 2.4 bn | 5.8% |
| Neurology | 10.0% | 8.6% | USD 1.2 bn | 10.8% |
| Other | 8.0% | 4.8% | USD 968 mn | 6.8% |
By source
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Reactor-produced | 34.0% | 28.0% | USD 4.1 bn | 10.3% |
| Cyclotron-produced | 38.0% | 38.0% | USD 4.6 bn | 12.5% |
| Generator-based | 14.0% | 14.0% | USD 1.7 bn | 12.5% |
| Ac-225 and alpha emitters | 14.0% | 20.0% | USD 1.7 bn | 16.6% |
By delivery
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Injection | 78.0% | 80.0% | USD 9.4 bn | 12.8% |
| Oral | 12.0% | 10.0% | USD 1.5 bn | 10.5% |
| Inhalation and others | 10.0% | 10.0% | USD 1.2 bn | 12.5% |
Top 25 countries for radiopharmaceuticals by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 87.5% of 2026 revenue and the 25 countries below together hold 96.2%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 5.3 bn | 44.0% | USD 17.0 bn | 12.3% |
| 2 | China | USD 968 mn | 8.0% | USD 4.8 bn | 17.4% |
| 3 | Germany | USD 847 mn | 7.0% | USD 2.6 bn | 11.8% |
| 4 | Japan | USD 847 mn | 7.0% | USD 2.0 bn | 8.8% |
| 5 | France | USD 605 mn | 5.0% | USD 1.8 bn | 11.3% |
| 6 | Italy | USD 484 mn | 4.0% | USD 1.3 bn | 10.7% |
| 7 | United Kingdom | USD 484 mn | 4.0% | USD 1.5 bn | 12.2% |
| 8 | Spain | USD 363 mn | 3.0% | USD 1.1 bn | 11.7% |
| 9 | South Korea | USD 363 mn | 3.0% | USD 1.2 bn | 12.5% |
| 10 | Australia | USD 302 mn | 2.5% | USD 903 mn | 11.6% |
| 11 | Canada | USD 236 mn | 1.9% | USD 735 mn | 12.0% |
| 12 | Netherlands | USD 140 mn | 1.2% | USD 436 mn | 12.0% |
| 13 | Switzerland | USD 103 mn | 0.8% | USD 322 mn | 12.1% |
| 14 | Belgium | USD 83 mn | 0.7% | USD 259 mn | 12.0% |
| 15 | Mexico | USD 70 mn | 0.6% | USD 314 mn | 16.2% |
| 16 | Russia | USD 62 mn | 0.5% | USD 192 mn | 12.1% |
| 17 | Austria | USD 54 mn | 0.5% | USD 173 mn | 12.2% |
| 18 | Sweden | USD 50 mn | 0.4% | USD 153 mn | 11.9% |
| 19 | India | USD 45 mn | 0.4% | USD 200 mn | 16.2% |
| 20 | Taiwan | USD 42 mn | 0.3% | USD 130 mn | 11.8% |
| 21 | Turkey | USD 39 mn | 0.3% | USD 173 mn | 16.1% |
| 22 | Poland | USD 36 mn | 0.3% | USD 161 mn | 16.1% |
| 23 | Israel | USD 34 mn | 0.3% | USD 153 mn | 16.3% |
| 24 | Denmark | USD 33 mn | 0.3% | USD 102 mn | 12.1% |
| 25 | Thailand | USD 31 mn | 0.3% | USD 137 mn | 15.9% |
| Rest of world | USD 454 mn | 3.8% | USD 1.4 bn | 12.1% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Novartis
- GE HealthCare
- Lantheus
- Curium
- Bracco
- Cardinal Health
- Bayer
Group 2: Regional and specialist players
- Jubilant Radiopharma
- Eckert and Ziegler
- Telix Pharmaceuticals
- SOFIE
- PETNET Solutions
- ITM Isotope Technologies Munich
- BWXT Medical
- ANSTO
- NTP Radioisotopes
Group 3: Emerging and niche players
- Isotopia
- Clarity Pharmaceuticals
- NorthStar Medical Radioisotopes
- Radiopharm Theranostics
- Orano Med
- Perspective Therapeutics
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the radiopharmaceuticals market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 12.5% is calculated from the resulting values.
The market is divided by use, by isotope, by application, by source, by delivery. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the radiopharmaceuticals market?
The global radiopharmaceuticals market is estimated at USD 10.8 bn in 2025 and USD 12.1 bn in 2026.
How fast will the radiopharmaceuticals market grow?
It is forecast to reach USD 39.3 bn by 2036, a compound annual growth rate of 12.5% from 2026, an increase of USD 27.2 bn.
Which country is the largest market for radiopharmaceuticals?
United States is the largest market by revenue at USD 5.3 bn in 2026, 44.0% of the global total. The three largest countries together hold 59.0%.
Which country is growing fastest?
Among the ten largest markets, China is growing fastest at 17.4% a year from 2026 to 2036.
Which radiopharmaceuticals segment is largest?
In the by use split, Therapeutic is the largest segment with 36.0% of 2026 revenue.
Who are the leading radiopharmaceuticals companies?
Global leaders include Novartis, GE HealthCare, Lantheus, Curium.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Oligonucleotide TherapeuticsUSD 12.2 bn · 16.0% CAGR
- Sterilization EquipmentUSD 11.7 bn · 6.0% CAGR
- ChromatographyUSD 12.6 bn · 6.0% CAGR
- Polymerase Chain ReactionUSD 11.6 bn · 6.5% CAGR
- Implantable Drug DeliveryUSD 12.9 bn · 7.8% CAGR
- Gene TherapyUSD 11.3 bn · 22.0% CAGR
- RNA TherapeuticsUSD 13.4 bn · 18.0% CAGR
- BioreactorUSD 13.7 bn · 10.0% CAGR